RxSight, Inc. (NASDAQ:RXST - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $14.42, but opened at $14.02. RxSight shares last traded at $14.55, with a volume of 62,218 shares changing hands.
Analyst Ratings Changes
A number of brokerages recently commented on RXST. Wells Fargo & Company decreased their price target on RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 3rd. Bank of America reaffirmed an "underperform" rating and set a $22.00 price target (down previously from $36.00) on shares of RxSight in a report on Thursday, April 3rd. JPMorgan Chase & Co. reissued an "underweight" rating and issued a $17.00 price objective (down from $40.00) on shares of RxSight in a research note on Friday, April 4th. UBS Group cut RxSight from a "buy" rating to a "neutral" rating and cut their target price for the stock from $45.00 to $16.00 in a research note on Wednesday, April 9th. Finally, Stifel Nicolaus decreased their price target on RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, RxSight presently has a consensus rating of "Hold" and a consensus price target of $37.60.
Check Out Our Latest Report on RxSight
RxSight Trading Down 0.6 %
The stock has a market capitalization of $584.29 million, a price-to-earnings ratio of -17.39 and a beta of 1.26. The company's 50-day simple moving average is $23.77 and its 200-day simple moving average is $35.05.
RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The company had revenue of $40.21 million for the quarter, compared to the consensus estimate of $40.23 million. On average, equities research analysts expect that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.
Insider Transactions at RxSight
In other RxSight news, Director Tamara Fountain sold 7,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the transaction, the director now directly owns 24,793 shares in the company, valued at approximately $637,428.03. This represents a 22.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Shweta Maniar sold 3,519 shares of RxSight stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total transaction of $108,631.53. Following the completion of the sale, the director now owns 7,383 shares of the company's stock, valued at $227,913.21. This represents a 32.28 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.36% of the company's stock.
Institutional Investors Weigh In On RxSight
A number of large investors have recently bought and sold shares of RXST. Private Trust Co. NA bought a new position in shares of RxSight during the 4th quarter worth about $34,000. State of Wyoming bought a new position in RxSight in the fourth quarter worth approximately $37,000. Coppell Advisory Solutions LLC grew its stake in RxSight by 108.9% in the fourth quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company's stock valued at $44,000 after acquiring an additional 672 shares during the period. Arcadia Investment Management Corp MI bought a new stake in shares of RxSight during the fourth quarter valued at approximately $46,000. Finally, Harbor Investment Advisory LLC acquired a new position in shares of RxSight during the fourth quarter worth approximately $52,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.
About RxSight
(
Get Free Report)
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
See Also
Before you consider RxSight, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.
While RxSight currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
